CBS 2019
CBSMD教育中心
中 文

Transcatheter Aortic Valve Replacement

Abstract

Recommended Article

Impact of myocardial fibrosis on left ventricular remodelling, recovery, and outcome after transcatheter aortic valve implantation in different haemodynamic subtypes of severe aortic stenosis Relationship between B-type natriuretic peptide and invasive haemodynamics in patients with severe aortic valve stenosis Incidence, predictors, and outcomes associated with acute kidney injury in patients undergoing transcatheter aortic valve replacement: from the BRAVO-3 randomized trial Bioprosthetic valve oversizing is associated with increased risk of valve thrombosis following TAVR Temporal Trends in Transcatheter Aortic Valve Replacement in France: FRANCE 2 to FRANCE TAVI Transcatheter Versus Surgical Aortic Valve Replacement in Low-Risk Patients Anticoagulation After Surgical or Transcatheter Bioprosthetic Aortic Valve Replacement Why and How to Measure Aortic Valve Calcification in Patients With Aortic Stenosis

EditorialMay 2, 2019

JOURNAL:N Engl J Med. Article Link

Informed Shared Decisions for Patients with Aortic Stenosis

CM Otto. Keywords: symptomatic aortic stenosis; TAVR; SAVR;

First 100 Words


Valve replacement is the only effective treatment for adults with severe, symptomatic aortic stenosis. The ideal prosthetic valve would be associated with minimal risk and discomfort at implantation, would have hemodynamics similar to those of a normal valve, would not require anticoagulation, and would be durable for the patient’s lifetime. We are moving closer to this goal, as evidenced by sequential randomized clinical trials of transcatheter aortic-valve replacement (TAVR), initially in patients at prohibitive or high estimated risk for death with surgical aortic-valve replacement, then in patients at intermediate risk, and now — in the trials by Mack et al.